Skip to main content
Veeva Systems Inc (VEEV)
Computer Software and Services Information Technology
Stock AI

Veeva Systems Unveils Keynote Speakers for the 2025 Commercial Summit

Last updated: May 06, 2025
Taurigo

Veeva Systems Inc. (NYSE: VEEV) is set to host its highly anticipated 2025 Veeva Commercial Summit on May 13-14 in Boston, where leading figures from the life sciences sector will gather to discuss innovative strategies for enhancing customer engagement through the integration of artificial intelligence (AI) and data alignment. This annual summit has become one of North America's premier events for commercial and medical affairs leaders in the life sciences industry.

1. Keynote Highlights: Pioneering AI Integration

The summit will feature Veeva's CEO, Peter Gassner, as the opening keynote speaker. Gassner will focus on Veeva's significant initiatives aimed at integrating AI into the Vault Platform and various Veeva applications. This includes ongoing advancements within Veeva Commercial Cloud and Veeva Data Cloud, which are designed to facilitate a more seamless and efficient approach to customer engagement.

2. Industry Leaders Share Insights

Attendees can expect to hear from a range of industry leaders presenting their experiences and strategies:

  • AstraZeneca will discuss the standardization of analytics across its brands to enhance marketing reach and performance.
  • Bayer will share insights on how they are driving customer-centric engagement through their Vault CRM.
  • Boehringer Ingelheim aims to showcase how scientific insights can be effectively connected across medical channels to facilitate personalized key opinion leader conversations.
  • Lilly is set to present its approach to integrating its content ecosystem by streamlining workflows and aligning global teams for impactful experiences at scale.
  • Johnson & Johnson and Madrigal will provide insights into building a modern data foundation that delivers connected insights for improved efficiency and field impact.

Additionally, emerging biopharma companies such as ANI Pharmaceuticals, Gamida Cell, NewAmsterdam Pharma, Orchard Therapeutics, and Sobi will share their go-to-market best practices, particularly focusing on strategies relevant for biotech launches.

3. Driving Unified Engagement

Matt Farrell, president of Veeva Commercial Cloud, emphasized the importance of collaboration across sales, marketing, and medical teams. "By connecting these functions, field teams can seamlessly work together to drive more effective, customer-centric experiences," he said. The summit aims to foster dialogue among industry professionals, encouraging the exchange of ideas and advancements in AI and data utilization.

4. Registration and Agenda

The Veeva Commercial Summit is poised to be a significant event for life sciences professionals looking to enhance their operational strategies and customer engagement methodologies. Those interested in attending can register and access the full agenda at veeva.com/Summit.

5. About Veeva Systems

Veeva Systems is recognized as a global leader in cloud software tailored for the life sciences industry. With a commitment to innovation and customer success, Veeva serves over 1,000 customers, including some of the world's largest biopharmaceutical companies and emerging biotech firms. As a Public Benefit Corporation, Veeva strives to balance the interests of all stakeholders, including customers, employees, and shareholders.

The upcoming summit promises to be an enriching experience for all attendees, marking a crucial step towards advancing unified engagement in the life sciences sector.

You may also be interested in:
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.